LMLorenza Marotti

Lorenza Marotti

*This is an algorithmically generated author record based on publicly available information.

Lorenza Marotti has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Survival and Extent of Breast Surgery in Patients with Complete Response After Neoadjuvant Therapy: A Retrospective Analysis from the EUSOMA Database

    by Federica Martorana, Damiano Gentile, Mariano Tomatis, Antonio Ponti, Lorenza Marotti, Cynthia Aristei, Nicolò Matteo Luca Battisti, Kwok Leung Cheung, Olaf Johan Hartmann, Isabel T. Rubio, et al.

    Background: Optimal management of breast cancer (BC) patients with pathological complete response (pCR) after neoadjuvant therapy (NAT) remains debated. We performed a retrospective analysis to evaluate whether the extent of surgery influences survival outcomes in this patient population. Methods: Using the EUSOMA database, we retrospectively collected data of women with pCR after NAT, excluding those with BRCA1/2 mutations. The cohort was stratified by surgery type, i.e., breast-conserving surgery (BCS) or mastectomy. Relapse-free survival (RFS) and overall survival (OS) were compared using Cox regression. Results: Of 467 patients, 327 (70.0%) underwent BCS and 140 (30.0%) underwent mastectomy. Women treated with mastectomy were more likely to have multifocal tumors and advanced disease. After a median follow-up of 5.6 years, 7.3% of patients experienced BC recurrence. Axillary nodal involvement (cN+) and mastectomy were independently associated with recurrence, occurring in 11.4% of cN+ compared to 3.7% of cN0 patients (HR 3.02; 95% CI: 1.40–6.51; p = 0.005) and in 12.5% of mastectomy vs. 5.2% of BCS patients (HR 2.08; 95% CI: 1.05–4.11; p 0.035). cN+ patients also showed significantly higher mortality rates (9.4% vs. 1.6% of cN0; HR 6.16; 95%CI: 2.09–18.17; p = 0.001). However, surgery type did not impact OS. Conclusions: In this cohort of BC patients with pCR after NAT, BCS was not associated with a higher risk of recurrence compared with mastectomy. Baseline nodal involvement independently predicted recurrence and mortality; however, the type of surgery did not impact OS. These findings support BCS as a safe treatment option for this patient population.

  • Management of the axilla in breast cancer patients: critical review, regional modified Delphi consensus and implementation in the Tuscan breast network

    by Matteo Ghilli, Carlotta Becherini, Icro Meattini, Catia Angiolini, Carmelo Bengala, Aroldo Marconi, Lorenzo Galli, Giovanni Angiolucci, Luigi Coltelli, Simona Borghesi, et al.

    Purpose Data from recently trials have provided practice-changing recommendations in management of the axilla in early breast cancer (eBC). However, further controversies have been raised, resulting in heterogeneous diffusion of these recommendations. Our purpose was to obtain a better homogeneity. Material and methods In 2021, the Tuscan Breast Network (TBN) established a consensus with the aim to update recommendations in this area. We performed a literature review on axillary management in eBC patients which led to an expert Delphi consensus aiming to explore the gray areas, build consensus and propose evidence-based suggestions for an appropriate management. Thereafter, we investigate their implementation in clinical practice. Results (1) DCIS patients should have SLN biopsy only in case of mastectomy or in conservative surgery if tumor is in a location that would preclude future nodal sampling or in case of a mass; (2) ALND may be omitted for 1–2 positive SLN patients undergoing BCS in T1-2 tumors with 1–2 SLN positive, eligible for whole-breast irradiation and adjuvant systemic therapies; (3) consider the option of RNI in patients with 1–3 positive lymph nodes and one or more high-risk characteristics; (4) the population identified in 2) should NOT undergo lymph node irradiation as an alternative to axillary surgery and (5) patients with clinically (pre-operatively) positive axilla, or undergoing primary systemic therapy, or outside the criteria reported in 2) must receive additional ALND and/or RT as per local policy. Conclusion This consensus provided a practical tool to stimulate local and national breast surgical and radiotherapy protocols.


  • International Criteria for Excellence Breast Centres

    by Lorenza Marotti, Isabel Teresa Rubio, Luigi Cataliotti

  • Aesthetic results following breast cancer surgery: A prospective study on 6515 cases from ten Italian Senonetwork breast centers

    by M. Serra, A. Quattrini Li, L. Cataliotti, E. Cianchetti, F. Corsi, R. De Vita, L. Fabiocchi, L. Fortunato, D. Friedman, M. Klinger, et al.


  • Data managers: A survey of the European Society of Breast Cancer Specialists in certified multi-disciplinary breast centers

    by Gabriele Schnapper, Lorenza Marotti, Denise Casella, Maria P. Mano, Robert E. Mansel, Antonio Ponti, The Eusoma Breast Centers Network Data Managers, V. Baldini, L.G. Bassani, E. Bissolotti, et al.

    The European Society of Breast Cancer Specialists (EUSOMA) requires that the breast centers' core team includes a trained person responsible for data collection and analysis. We addressed a questionnaire to the data managers of the EUSOMA breast centers network in order to acquire information with regard to their education, training, role, activity, recognition, and satisfaction. Breast centers' data managers are highly educated individuals with a variety of backgrounds carrying out, more frequently part‐time and as temporary employees, a job for which they received little specific training. These findings support the importance of defining a core curriculum and a training program.